<DOC>
	<DOCNO>NCT00237484</DOCNO>
	<brief_summary>This Phase IIIB , randomize , prospective , multicenter , single-country , open-label , control pilot trial design evaluate effect infliximab induction therapy sustain virologic response ( SVR ) treatment pegylated interferon alfa-2b plus ribavirin group 96 therapy-naïve subject genotype 1 hepatitis C virus ( HCV ) infection high serum tumor necrosis factor ( TNF ) -alpha value .</brief_summary>
	<brief_title>Effect Infliximab Efficacy Peg-Intron/Ribavirin Patients With Hepatitis C ( Study P04257AM4 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Subjects must demonstrate willingness participate study comply procedure sign write informed consent . Subjects must 18 65 year age . HCV genotype 1 ( include mixture subtypes genotype 1 ) . Naïve interferon ( formulation ) ribavirin . Serum TNFalpha &gt; 300 pg/mL ( single measure PreScreen Visit ) . HCV ribonucleic acid ( RNA ) positive . Any alanine aminotransferase ( ALT ) level . Fasting glucose 3.86.2 mmol/L . Results 6.37.8 mmol/L require HbA1c &lt; =8.5 % . All diabetic subject must HbA1c &lt; =8.5 % , whether medication diet control . Liver biopsy within 24 month enrolment demonstrate Stage 03 fibrosis ( Metavir System ) . Compensated liver disease follow minimum hematological , biochemical , serological criterion screen visit ( WNL = within normal limit ) : Hemoglobin value equal 12 g/dL female 13 g/dL male . White blood cell ( WBC ) count equal 3,000/mm**3 Neutrophil count equal 1,500/mm**3 Platelet count equal 80,000/mm**3 Total bilirubin WNL Indirect bilirubin WNL ( unless nonhepatitis related factor Gilbert 's disease explain indirect bilirubin rise ) . In case indirect bilirubin less equal 50 µmol/L Albumin WNL Serum creatinine WNL Women childbearing potential ( include woman less 1 year postmenopausal woman become sexually active ) must willing use acceptable method birth control , deem acceptable investigator , ( e.g. , hormonal contraceptive , medically prescribe intrauterine device ( IUD ) , condom combination spermicidal ) surgically sterilize ( e.g. , hysterectomy tubal ligation ) . Subjects must understand able adhere dose visit schedule , agree record , study medication compliance , concomitant medication , adverse event accurately consistently daily diary . Women pregnant nursing . Subjects observed designate washout period prohibit medication . Subjects use investigational product within 30 day prior enrollment . Acute HCV infection define infection &lt; 6 month . Male partner to/or Heterosexually active woman childbearing potential practicing highly effective form contraception . Positive screen tuberculosis ( TB ) Tuberculin Skin Test &gt; 5mm . History presence cirrhosis ( Stage 4 Metavir System ) and/or complication ascites , bleed varix hepatic encephalopathy Active hepatitis B virus ( HBV ) infection ( hepatitis B surface antigen [ HBsAg ] positive ) . Any known preexisting psychiatric condition could interfere subject 's participation completion study : Preexisting psychiatric condition , include limited moderate severe depression , history severe psychiatric disorder , psychosis , suicidal ideation and/or suicidal attempt Severe depression include follow : Hospitalization depression , Electro convulsive therapy depression , Depression result prolonged absence work and/or significant disruption daily function . Subjects uncontrolled hypertension and/or diabetes . Alcohol consumption &gt; 50 g/day . Nonprescription injection drug use past 6 month . HIV antibody positive . Previous Infliximab antiTNF treatment , previous interferon ; Pegylated interferon alfa2b ribavirin form . Clinically significant impairment cardiac renal function , central nervous system , pulmonary , immunological , vascular gastrointestinal disease . Current malignancy ( resect cutaneous basal , squamous cell carcinoma and/or situ cervical cancer ) . Use illicit drug , investigator 's opinion , may interfere compliance study procedure . Any condition , opinion physician , would make subject unsuitable enrollment could interfere subject participate completing study . Have show previous immediate hypersensitivity response , include anaphylaxis , immunoglobulin product ( plasmaderived recombinant , e.g. , monoclonal antibody ) . Have know allergy murine protein chimeric protein . Have follow infection within 6 month screen : herpes zoster [ shingle ] , cytomegalovirus , Pneumocystis carinii , aspergillosis , histoplasmosis , mycobacteria TB . Have transplant organ ( exception corneal transplant perform &gt; 3 month prior screen ) . Have concomitant diagnosis history congestive heart failure ( CHF ) . History noncompliance medical regimen , condition/circumstance could interfere patient 's adherence protocol requirement ( e.g. , psychiatric disease , lack motivation , travel , etc ) . Any cause liver disease chronic hepatitis C , include limited : Hemochromatosis Alpha1 antitrypsin deficiency Wilson 's disease Autoimmune hepatitis Alcoholic liver disease Nonalcoholic steatohepatitis ( NASH ) Drugrelated liver disease Subject positive TST might enrol diagnosis tuberculosis rule . To rule TB , follow criterion must meet : The medical history negative symptom TB The physical examination must reveal observation could relate TB The patient document adequate course treatment either LTBI TB least 6 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pegylated interferon alfa-2b</keyword>
	<keyword>ribavirin</keyword>
	<keyword>infliximab</keyword>
	<keyword>chronic hepatitis C</keyword>
</DOC>